Skip to main content
Find more clinical trials

Blood-Brain Barrier Permeability Imaging for Early Alzheimer's

Start: December 18, 2018
End: February 28, 2022
Enrollment: 60

What Is This Study About?

Disruption of the blood-brain barrier, which is important for protecting the brain, could be an early process that precedes Alzheimer's disease. This study will test a method for measuring disruptions to the blood-brain barrier using advanced magnetic resonance imaging (MRI) methods in cognitively normal younger and older adults and adults with mild cognitive impairment (MCI), a condition that puts people at higher risk for Alzheimer's. Participants will undergo an MRI brain scan for up to 60 minutes that employs an imaging technique called GRASP DCE-MRI (golden-angle radial sparse parallel dynamic contrast agent-enhanced MRI). Researchers will compare the patterns of blood-brain barrier permeability, or disruption, in normal versus abnormal aging.

Do I Qualify To Participate in This Study?

Minimum Age: 20 Years

Maximum Age: 85 Years

Must have:

  • Diagnosed with amnestic MCI

Must NOT have:

  • Pregnant, planning to get pregnant, or nursing
  • Claustrophobia
  • Heart pacemaker
  • Intracranial clips, metal implants, unremovable jewelry, metal in eyes
  • History or presence of any other major medical, neurologic, or psychiatric conditions, such as Alzheimer's, Parkinson's, or stroke
  • Kidney or liver disease as this may cause concerns related to the contrast agent
  • Allergy to the MRI contrast agent gadolinium

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Charles Morton
Danielle Costanzo

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

New York
New York University School of Medicine
New York, NY 10016
Recruiting
Charles Morton

Who Sponsors This Study?

Lead: NYU Langone Health

Source: ClinicalTrials.gov ID: NCT03389698